WuXi Biologics to Install Industry’s Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility

21-Mar-2018 Intellasia | BusinessWire | 7:00 AM Print This Post

WUXI, China & BETHLEHEM, Pa.–(BUSINESS WIRE)–#biopharmaceuticalWuXi
(2269.HK), a leading global open-access biologics
technology platform company offering end-to-end solutions for biologics
discovery, development and manufacturing, today announced that it has
selected 4,000 liter (L) Custom
Single Run (CSR®)
disposable bioreactors from ABEC
for its new commercial manufacturing facility (MFG4) in Wuxi city,
Jiangsu, China. The partnership followed WuXi Biologics’ successful
testing and evaluation of ABEC’s CSR bioreactor technology.

The 4,000L CSR is the largest single-use bioreactor size available in
the industry and potentially largest-ever design in conventional
disposable bioreactors, resulting in higher productivity and
significantly lowering the cost of goods for cell culture-based
biopharmaceuticals. The system also delivers performance comparable to
stainless steel systems of that scale and can be fully customized for
different products, resulting in higher cell culture productivity and
faster process transfer and scale-up. With the scale-out strategy that
WuXi Biologics pioneered in the industry to use multiple disposable
bioreactors for commercial manufacturing, 4,000L CSRs will enable
manufacturing up to the scale of 24,000L comparable to traditional
stainless steel bioreactors yet still achieving the advantages of CAPEX
and timeline reduction benefited from disposables.

Dr. Chris Chen, CEO of WuXi Biologics, said, “We are proud to be a
global technology leader in bioprocessing and the first company in Asia
to advance this exciting new technology. ABEC’s large volume single-use
bioreactor greatly enhances our commercial manufacturing potential by
allowing not only scale-out of capacity but also scale-up. In addition
to the flexibility and time to market benefits of single-use
manufacturing, we can now offer our clients true economies of scale and
address biologics supply needs from kilograms to tons.”

“WuXi Biologics’ successful testing, evaluation and investment
further validates ABEC’s CSR technology as one of the most flexible
single-use solutions available on the market,”
said Scott Pickering,
ABEC President and CEO. “We are pleased to be part of their
next-generation manufacturing strategy, and look forward to continuing
this long-term partnership.”

About WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access
biologics technology platform in the world offering end-to-end solutions
to empower organizations to discover develop and manufacture biologics
from concept to commercial manufacturing. Our company history and
achievements demonstrate our commitment to providing a truly ONE-stop
service offering and value proposition to our global clients. For more
information on WuXi Biologics, please visit www.wuxibiologics.com.

About ABEC

Since 1974, ABEC has been a leader in delivering integrated process
solutions and services for manufacturing in the biopharmaceutical
industry. A majority of the world’s pharmaceutical and biotech companies
are ABEC customers with many of today’s leading therapies manufactured
by processes and equipment engineered, manufactured, installed and
serviced by ABEC. ABEC’s unique value is based on long experience,
complete in-house capabilities, a custom, flexible approach, and
long-term credibility. Whether adding capacity or improving existing
facilities ABEC’s turn-key solutions and support services reduce overall
cost and time to market while delivering maximum productivity. www.abecsingleuse.com.


WuXi Biologics
Jia Li, +86-21-2066-4528
[email protected]
Cooper Curcio, +1 610-861-4666
[email protected]


Category: BusinessWire, PRAsia

Print This Post

Comments are closed.